Kymera Therapeutics Presents New Preclinical Data for KT-579
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader, at the American College of Rheumatology Annual Meeting.
KT-579 demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies.
- KT-579 is a potent, selective, oral degrader of IRF5.
- Phase 1 testing for KT-579 is expected to begin in early 2026.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) advances a new class of oral small molecule degrader medicines for immunological diseases.
Author's summary: Kymera Therapeutics presents new preclinical data for KT-579.
More News
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Australia is Suing Microsoft Over Misleading Microsoft 365 Price Hikes
- Elon Musk could step down if Tesla pay plan is rejected
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- The environmental impact of the 2026 World Cup
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Staffordshire Leader Reacts to "Squandered" Billions of Taxpayers' Money on Asylum Hotels - Staffordshire County Council Newsroom